Li Li
Jade Biosciences · Second Hospital of Shanxi Medical University · Jade BioSciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Li Li as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:59 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07902817 · A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyJade Biosciences, Inc. · recruiting · IgA Nephropathy (IgAN) · study director
- N/ANCT07833930 · Incidence and Clinical Features of Breakthrough Pain After Brachial Plexus Block in Diabetic PatientsSecond Hospital of Shanxi Medical University · recruiting · Postoperative Pain · study director
- Ph2NCT07541287 · A Study of JADE101 in Participants With Immunoglobulin A NephropathyJade Biosciences, Inc. · recruiting · IgA Nephropathy · study director
- Ph1NCT07525947 · A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese ParticipantsJade Biosciences, Inc. · recruiting · Healthy Volunteers (HV) · study director
- N/ANCT07490938 · Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint PainFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine · recruiting · Breast Cancer Survivors, Endocrine Therapy-Induced Joint Pain · study chair
- Ph4NCT07485335 · A Bundled Intervention to End Opioid OverdosesUniversity of Alabama at Birmingham · recruiting · Opioid Use Disorder, Opioid Overdose · principal investigator
- Ph1NCT07059312 · A Phase 1 Study of JADE101 in Healthy ParticipantsJade Biosciences, Inc. · active not recruiting · Healthy Volunteers · study director
- N/ANCT06737848 · The Comparison of Single Catheter and Double Catheter Adrenal Vein Sampling Methods Based on the Upper Limb ApproachArmy Medical University, China · not yet recruiting · Primary Aldosteronism · study director
- Ph3NCT06697522 · Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in ChildrenOcumension Therapeutics (Suzhou) Co., Ltd · completed · Myopia · principal investigator
- Ph1NCT06678581 · SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese SubjectsShanton Pharma Co., Ltd. · completed · Gout, Hyperuricemia · study director
- N/ANCT06669923 · Understanding Sugar-Sweetened Beverages (SSB) and Colorectal Cancer (CRC)University of Virginia · not yet recruiting · Colorectal Neoplasms · principal investigator
- Ph4NCT06593093 · A Bundled InterventionUniversity of Alabama at Birmingham · completed · Opioid Use Disorder, Opioid Overdose · principal investigator
- N/ANCT06427018 · Expressions of Ezrin and Pip5k1α Proteins in Airway Smooth Muscle of Asthmatic PatientsLei-Miao Yin · recruiting · Asthma, Protein · study director
- N/ANCT06423547 · Risk Warning Model of Postoperative Delirium and Long-term Cognitive Dysfunction in Elderly PatientsXuanwu Hospital, Beijing · recruiting · Postoperative Delirium, Postoperative Neurocognitive Disorder, Surgery · principal investigator
- N/ANCT06371313 · Endocrine, Metabolic and Inflammatory Characteristics of Offspring of Mothers With PCOS HyperandrogenismGuangdong Women and Children Hospital · completed · PCOS · study chair
- N/ANCT05987046 · Contrast Training, Post-activation Countermovement Jump Performance in High Strength MaleNational Taiwan Sport University · completed · Resistance Training · study director
- N/ANCT05902689 · Application of Sticky Bone and Bio-Oss Collagen in Alveolar Ridge PreservationSecond Affiliated Hospital, Zhejiang University, School of Medicine · completed · Alveolar Bone Resorption · study director
- Ph1/Ph2NCT05571540 · Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALLKunming Hope of Health Hospital · withdrawn · B-cell Acute Lymphoblastic Leukemia, B-ALL · principal investigator
- Ph1/Ph2NCT05570188 · Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic MalignanciesKunming Hope of Health Hospital · withdrawn · B-cell Lymphoma, B-cell Leukemia · principal investigator
- N/ANCT05561855 · T2DM Intensity Lifestyle InterventionNingbo No. 1 Hospital · completed · Diabetes Mellitus, Type 2, Overweight or Obesity · principal investigator
- N/ANCT05516641 · Prebiotics in Rectal CancerOchsner Health System · unknown · Rectal Cancer · principal investigator
- Early Ph1NCT05507996 · Recombinant Adeno-associated Virus Administration for Patients With Menkes SyndromeKunming Hope of Health Hospital · terminated · Menkes Syndrome · principal investigator
- N/ANCT05401266 · The Effect of Mild Hypercapnia During Anesthetic Emergence on Recovery Time From TIVASecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · Total Intravenous Anesthesia · study director
- N/ANCT05315492 · Strengthening Community Addiction Services in VietnamUniversity of California, Los Angeles · completed · Addiction, Opioid · principal investigator
- Ph2NCT05302011 · Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaPeking Union Medical College Hospital · completed · Esophageal Squamous Cell Carcinoma · study chair
- N/ANCT05219136 · Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting ProtocolChanghai Hospital · completed · Gastroscopy, Feelings, Fasting · principal investigator
- N/ANCT04325360 · Effects of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Refractory EpilepsyUniversity of Campinas, Brazil · unknown · Epilepsy Intractable · study director
- N/ANCT04283682 · Intervention Facilitates Oral Feeding in Premature InfantsChildren's Hospital of Fudan University · completed · Premature · study chair
- N/ANCT04187599 · Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)CooperVision International Limited (CVIL) · recruiting · Myopia · principal investigator
- Ph4NCT04146155 · Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial DiseaseSecond Affiliated Hospital, Zhejiang University, School of Medicine · unknown · Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus · principal investigator
- Ph4NCT03377257 · Efficacy and Safety of Zolmitriptan by Sublingual AdministrationXijing Hospital · unknown · Cluster Headache · principal investigator
- N/ANCT03293355 · Multilevel Integration Strategies to Enhance Service Provider Networks in VietnamUniversity of California, Los Angeles · completed · Linkage to Care · principal investigator
- N/ANCT03061266 · The Application of the E-health Education on Shared Care Program for Patients With Type 2 DiabetesLi-Li Chen · unknown · Type 2 Diabetes Mellitus · study director
- N/ANCT02596347 · The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD)National Jewish Health · completed · Chronic Beryllium Disease (CBD), Beryllium Sensitization (BeS) · principal investigator
- N/ANCT02584946 · Avenanthramides and ExercisePepsiCo Global R&D · completed · Avenanthramides · principal investigator
- N/ANCT02415374 · Bioavailability and Metabolism of Avenanthramide: a Novel Oat PhytochemicalPepsiCo Global R&D · completed · Bioavailability, Metabolism, Avenanthramides · principal investigator
- N/ANCT02130921 · Enhancing the Role of Commune Health Workers in HIV and Drug Control: A Randomized Controlled TrialUniversity of California, Los Angeles · completed · Drug Dependence · principal investigator
- N/ANCT01762553 · TEA for Families and Children: A Randomized Intervention TrialUniversity of California, Los Angeles · completed · Behaviors, Health · principal investigator
- Ph1/Ph2NCT01540188 · Development of a Family Intervention to Address Drug Use and HIV in VietnamUniversity of California, Los Angeles · completed · Quality of Life · principal investigator
- N/ANCT01532609 · Methadone Maintenance and HIV Prevention: A Window of Opportunity in ChinaUniversity of California, Los Angeles · completed · Capacity Building, Drug Use, HIV/AIDS · principal investigator
- N/ANCT01068067 · Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Renal Transplant RecipientsSun Yat-sen University · unknown · Renal Transplantation · principal investigator
- N/ANCT01052415 · POL and Access Intervention to Reduce HIV Stigma Among Service Providers in ChinaUniversity of California, Los Angeles · completed · HIV-related Stigma, Patient Satisfaction, Provider-patient Interaction · principal investigator
- N/ANCT01037946 · Family to Family: Psychoeducation to Improve Children's Outcomes in HIV+ FamiliesUniversity of California, Los Angeles · completed · Quality of Life, Family Relations, Mental Health · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 327 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Multi-target repetitive Transcranial Magnetic Stimulation (rTMS) treatment for Major Depressive Disorder (MDD) and comorbid painK01MH123887 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2026 to 2027 · $182,887 awarded in 2027Same name and institution; not confirmed by an ID
- 13/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT MUSCU01DA041093 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · fiscal years 2026 · $1,118,269 awarded in 2026Same name and institution; not confirmed by an ID
- A Bundled Intervention to End Opioid Overdoses by Increasing Treatment Uptake Post Emergency Department DischargeR33DA062351 · NIDA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2026 · $679,331 awarded in 2026Grant number is on one of their registry trials
- A novel molecularly targeted theranostic approach via the alphavbeta6 integrin for the detection and treatment of metastatic cancersR01CA279342 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2026 · $590,125 awarded in 2026Same name and institution; not confirmed by an ID
- Acute and Long-Term Impact of SARS-CoV-2 Infection and its Interaction with APOE on Cognitive Function and Neuropathology in Aging and Alzheimer's DiseaseR01AG077772 · NIA · UNIVERSITY OF MINNESOTA · fiscal years 2026 · $700,148 awarded in 2026Same name and institution; not confirmed by an ID
- Administrative CoreP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2026 · $196,503 awarded in 2026Same name and institution; not confirmed by an ID
- AI-accelerated optical simulation for fast timing nuclear imagingR01EB034475 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2025 to 2026 · $615,952 awarded in 2026Same name and institution; not confirmed by an ID
- Cancer Center Administration (Admin)P30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2026 · $337,110 awarded in 2026Same name and institution; not confirmed by an ID
- Causes and consequences of microbe-mediated asexualityR35GM150991 · NIGMS · UNIVERSITY OF MINNESOTA · fiscal years 2026 · $386,024 awarded in 2026Same name and institution; not confirmed by an ID
- Chromatin remodeling factor CHD7 regulates cardiac and craniofacial lymphatic vessel developmentR01HL176018 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · fiscal years 2026 · $662,016 awarded in 2026Same name and institution; not confirmed by an ID
- Core A: Administration, Communication and Project ManagementP01CA281826 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2026 · $365,343 awarded in 2026Same name and institution; not confirmed by an ID
- Creation of a monkey mini mental state exam (mMMSE) for identifying early cognitive deficits related to Alzheimer’s disease and related dementiasR33AG078471 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2026 · $714,542 awarded in 2026Same name and institution; not confirmed by an ID
- Determining themechanism of maternal IL-10 restriction of fetal emergency myelopoiesis to improve neonataloutcomesR01HD116402 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2026 · $417,462 awarded in 2026Same name and institution; not confirmed by an ID
- Developing Novel High-dimensional Integrative Mediation Analysis Methods and Tools for Cardiovascular DiseasesR01HL184065 · NHLBI · UNIVERSITY OF MINNESOTA · fiscal years 2026 · $657,595 awarded in 2026Same name and institution; not confirmed by an ID
- Development of novel endolysins targeting Cutibacterium acnes to treat acne vulgarisR44AR082722 · NIAMS · TOPAZ BIOSCIENCES, INC. · fiscal years 2026 · $576,499 awarded in 2026Same name and institution; not confirmed by an ID
- ELAVL1 role in glioblastoma heterogeneity through intercellular gene transfer mediated by cell fusion and tunneling membrane nanotube formationR01CA269365 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2026 · $339,694 awarded in 2026Same name and institution; not confirmed by an ID
- Elucidating locus coeruleus homeostatic mechanisms in opioid-induced sleep disturbancesR01DA061865 · NIDA · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2026 · $574,954 awarded in 2026Same name and institution; not confirmed by an ID
- Engineering Tunable Biomimetic Adhesive Hydrogel to Deliver and Enhance MSC Function for Corneal RegenerationR01EY038446 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2026 · $527,987 awarded in 2026Same name and institution; not confirmed by an ID
- Evaluating pain communication and understanding in interpreted medical encounters in a pediatric emergency departmentF32HD114452 · NICHD · UNIVERSITY OF CALIFORNIA-IRVINE · fiscal years 2026 · $81,280 awarded in 2026Same name and institution; not confirmed by an ID
- Exploring the Link Between Extracellular Vesicle-Associated Inflammation in Obesity and Sepsis OutcomesR01DK143964 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2026 · $815,858 awarded in 2026Same name and institution; not confirmed by an ID
- Fetal Brain MRI as a Predictor of Late Neurodevelopmental Outcome in Congenital Heart DiseaseR01NS121334 · NINDS · BOSTON CHILDREN'S HOSPITAL · fiscal years 2025 to 2026 · $440,741 awarded in 2026Same name and institution; not confirmed by an ID
- Genetic dissection of motivational drive to eatR35GM138060 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2025 to 2026 · $451,000 awarded in 2026Same name and institution; not confirmed by an ID
- Hunger-Dependent Modulation of Neural Circuits for Social Visuomotor Processing in Schooling FishF31NS141340 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2025 to 2026 · $43,817 awarded in 2026Same name and institution; not confirmed by an ID
- Identifying and Restoring Mechanisms Driving DRPLA-Associated Epilepsy.R21NS147246 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2026 · $479,687 awarded in 2026Same name and institution; not confirmed by an ID
- Imaging early development of human neural circuitsR01HD109395 · NICHD · UNIVERSITY OF CALIFORNIA-IRVINE · fiscal years 2025 to 2026 · $414,683 awarded in 2026Same name and institution; not confirmed by an ID
- Impact of Mitochondrial Lipidomic Dynamics and its Interaction with APOE Isoforms on Brain Aging and Alzheimers DiseaseR01AG081426 · NIA · UNIVERSITY OF MINNESOTA · fiscal years 2026 · $645,802 awarded in 2026Same name and institution; not confirmed by an ID
- Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia.R37CA266550 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2026 · $675,576 awarded in 2026Same name and institution; not confirmed by an ID
- Investigating the Determinants of Response to Pan-RAS Inhibition in Juvenile Myelomonocytic LeukemiaR01CA316529 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2026 · $587,777 awarded in 2026Same name and institution; not confirmed by an ID
- Investigating the neural mechanisms of positive and negative social interactionsF30MH140515 · NIMH · UNIVERSITY OF CALIFORNIA-IRVINE · fiscal years 2025 to 2026 · $47,116 awarded in 2026Same name and institution; not confirmed by an ID
- Kinase regulators of retinal ganglion cell survival and axon regenerationR01EY035684 · NEI · BOSTON CHILDREN'S HOSPITAL · fiscal years 2025 to 2026 · $624,210 awarded in 2026Same name and institution; not confirmed by an ID
- Mechanisms of Hydra Development and RegenerationR35GM133689 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2026 · $442,849 awarded in 2026Same name and institution; not confirmed by an ID
- Mentoring Clinical Investigators in Patient-Oriented Adolescent Alcohol ResearchK24AA031052 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · fiscal years 2026 · $214,659 awarded in 2026Same name and institution; not confirmed by an ID
- Mentoring Patient-Oriented Research to Improve Neonatal Pulmonary OutcomesK24HL188310 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2026 · $128,466 awarded in 2026Same name and institution; not confirmed by an ID
- Mitotic transmission of acentric chromosomesR35GM139595 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · fiscal years 2026 · $423,182 awarded in 2026Same name and institution; not confirmed by an ID
- Modulating mitochondrial calcium in cardiac homeostasis and diseaseR01HL164491 · NHLBI · UNIVERSITY OF MINNESOTA · fiscal years 2026 · $429,564 awarded in 2026Same name and institution; not confirmed by an ID
- Molecular and Cellular Analysis CoreP30EY003039 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2026 · $160,434 awarded in 2026Same name and institution; not confirmed by an ID
- Optimizing Tracheal Intubation Outcomes and Neonatal Safety (OPTION SAFE)R01HD106996 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2026 · $698,802 awarded in 2026Same name and institution; not confirmed by an ID
- Perfusion CT for liver radioembolizationR21CA300717 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2026 · $409,141 awarded in 2026Same name and institution; not confirmed by an ID
- Post-transcriptional regulation of hepatokines and systemic metabolismR01DK144132 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2026 · $781,491 awarded in 2026Same name and institution; not confirmed by an ID
- Post-transcriptional regulation of LDLRR01HL174008 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2025 to 2026 · $752,913 awarded in 2026Same name and institution; not confirmed by an ID
- Predictive Models of Beryllium Sensitization and Chronic Beryllium DiseaseR01ES034767 · NIEHS · NATIONAL JEWISH HEALTH · fiscal years 2026 · $787,177 awarded in 2026Same name and institution; not confirmed by an ID
- PROSPER: Pulmonary Recovery and Outcomes after Severe Pediatric Respiratory IllnessR01HL183628 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2026 · $930,637 awarded in 2026Same name and institution; not confirmed by an ID
- Role of DHRS9 in oxylipin metabolismR01HL168031 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2025 to 2026 · $655,907 awarded in 2026Same name and institution; not confirmed by an ID
- SEER CORE INFRASTRUCTURE SUPPORT26120180001 · OD · UNIVERSITY OF SOUTHERN CALIFORNIA · fiscal years 2026 · $3,043,929 awarded in 2026Same name and institution; not confirmed by an ID
- Spatial subcellular mapping of the intestinal LncRNAomeDP2AI177910 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2025 to 2026 · $492,000 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting AMP Synthesis to Overcome Resistance to BH3 Mimetics in Acute Myeloid LeukemiaR01CA292893 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2026 · $713,836 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting Cholesterol Homeostasis to maintain vision in MS-like optic neuritisR01EY034194 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2025 to 2026 · $297,112 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting Protein Arginine Methyltransferases to Eradicate Acute Myeloid LeukemiaR01CA279595 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2026 · $708,057 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting the gut-liver axis in cardiovascular diseaseR01HL163908 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2026 · $725,001 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting Tiam1-mediated synaptic plasticity for the relief of opioid toleranceR01DA056673 · NIDA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2026 · $454,197 awarded in 2026Same name and institution; not confirmed by an ID
- The AHR-FADS3-DHA axis in Dendritic Cell limits T cell autoimmunityK99AI202584 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2026 · $130,140 awarded in 2026Same name and institution; not confirmed by an ID
- The BRCA Exchange Knowledgebase for Clinical Cancer GeneticsU24CA302705 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · fiscal years 2025 to 2026 · $645,954 awarded in 2026Same name and institution; not confirmed by an ID
- The conserved mechanisms underlying different types of chronic painR01NS124141 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2026 · $442,638 awarded in 2026Same name and institution; not confirmed by an ID
- The Pacific Cancer Research Consortium (PCRC), an NCORP Community SiteUG1CA189953 · NCI · SWEDISH MEDICAL CENTER, FIRST HILL · fiscal years 2026 · $2,606,426 awarded in 2026Same name and institution; not confirmed by an ID
- The Role of HIV Proteins in Psychostimulant AbuseR01DA062680 · NIDA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2026 · $766,280 awarded in 2026Same name and institution; not confirmed by an ID
- The Role of Microbiome Composition in Amphetamine AbuseR01DA056484 · NIDA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2026 · $536,379 awarded in 2026Same name and institution; not confirmed by an ID
- Type 2 diabetes induced chronic inflammation on stroke outcomeR01NS137082 · NINDS · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · fiscal years 2026 · $591,470 awarded in 2026Same name and institution; not confirmed by an ID
- UC Santa Cruz PREPR25GM104552 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · fiscal years 2025 to 2026 · $432,000 awarded in 2026Same name and institution; not confirmed by an ID
- Uncovering Architectural Features in Hyper-Adhesive DesmosomesF31AR088336 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2026 · $42,036 awarded in 2026Same name and institution; not confirmed by an ID
- Use of Oscillometry for the Evaluation of Pulmonary Function Following Pediatric Acute Respiratory Failure.R21HD118297 · NICHD · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2026 · $31,004 awarded in 2026Same name and institution; not confirmed by an ID
- A liver digital twin for personalized cancer therapyU01CA289068 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2025 · $716,666 awarded in 2025Same name and institution; not confirmed by an ID
- An animal model of early Alzheimer’s disease pathogenesis in the interoceptive-allostatic networkRF1AG078340 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2025 · $1,545,189 awarded in 2025Same name and institution; not confirmed by an ID
- Bacterial Community Barrier to Vancomycin Resistant EnterococcusR21AI180489 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · fiscal years 2025 · $231,250 awarded in 2025Same name and institution; not confirmed by an ID
- Dopaminergic Control of Glial Cells in Prefrontal Cortex FunctionsR21MH136486 · NIMH · UNIVERSITY OF CALIFORNIA-IRVINE · fiscal years 2025 · $117,750 awarded in 2025Same name and institution; not confirmed by an ID
- Enhanced Imaging of the Fetal Brain MicrostructureR01EB032366 · NIBIB · UNIVERSITY OF CALIFORNIA-IRVINE · fiscal years 2025 · $469,574 awarded in 2025Same name and institution; not confirmed by an ID
- In vivo testing of structure-based vaccine candidates targeting Alzheimer’s diseaseR21AG087044 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2025 · $356,174 awarded in 2025Same name and institution; not confirmed by an ID
- Probing the Effects of Pathological Conditions on AKTR35GM159958 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2025 · $2,011,691 awarded in 2025Same name and institution; not confirmed by an ID
- Strengthening Addiction Care Continuum through Community Consortium in VietnamR01DA050678 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2025 · $359,716 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- A Bundled Intervention to End Opioid Overdoses by Increasing Treatment Uptake Post Emergency Department DischargeR61DA062351 · NIDA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Li Li · fiscal years 2024Named on NCT06593093
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:59 UTC. The ranking covers the 200 most relevant of 2617 PubMed records, and a shared surname and initials can bring in a namesake. All 2617 on PubMed
- 251 citationsRCR 28.5
- 188 citationsRCR 23.0
- Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.N Engl J Med · 2025100 citationsRCR 24.3
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.N Engl J Med · 202599 citationsRCR 26.0
- 83 citationsRCR 27.3
- 77 citationsRCR 15.8
- Intravenous Tenecteplase before Thrombectomy in Stroke.N Engl J Med · 202564 citationsRCR 18.1
- 63 citationsRCR 13.8
- Cardiometabolic benefits of a non-industrialized-type diet are linked to gut microbiome modulation.Cell · 202558 citationsRCR 15.6
- A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.N Engl J Med · 202545 citationsRCR 11.9